The experts agreed that perioperative approaches in muscle-invasive bladder cancer continue to evolve. Ongoing data will ...
A subcutaneously injected version of Merck cancer immunotherapy Keytruda is now FDA approved, a regulatory decision that gives patients a less burdensome dosing option and provides the pharmaceutical ...
Muscle-invasive bladder cancer management is challenging for cisplatin-ineligible patients due to limited treatment options and high recurrence rates. The Padcev-Keytruda combination therapy ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback